Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials-Reference-Cited by-同舟云学术

Bleeding Outcomes in Patients Treated With Asundexian in Phase II Trials

Published:2024-02 Issue:6 Volume:83 Page:669-678
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Eikelboom John W.,Mundl Hardi,Alexander John H.,Caso Valeria,Connolly Stuart J.,Coppolecchia Rosa,Gebel Martin,Hart Robert G.,Holberg Gerlind,Keller Lars,Patel Manesh R.,Piccini Jonathan P.,Rao Sunil V.,Shoamanesh Ashkan,Tamm Miriam,Viethen Thomas,Yassen Ashraf,Bonaca Marc P.

Publisher

Elsevier BV

Reference10 articles.

1. Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week;Hsu;J Am Coll Cardiol,2021

2. Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study;Piccini;Lancet,2022

3. A multicenter, phase 2, randomized, placebo-controlled, double-blind, parallel-group, dose-finding trial of the oral factor XIa inhibitor asundexian to prevent adverse cardiovascular outcomes following acute myocardial infarction;Rao;Circulation,2022

4. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial;Shoamanesh;Lancet,2022

5. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A pharmacokinetic and pharmacodynamic evaluation of asundexian: a novel factor XIa inhibitor for stroke prevention;Expert Opinion on Drug Metabolism & Toxicology;2024-09-11

2. Atrial fibrillation and long-term cardiovascular outcomes: bringing the whole picture into focus;European Heart Journal;2024-06-07

3. Treatment strategies of the thromboembolic risk in kidney failure patients with atrial fibrillation;Nephrology Dialysis Transplantation;2024-05-30

4. Thrombosis, Bleeding, and the Promise of Factor XI(a) Inhibition;Journal of the American College of Cardiology;2024-02